Merck eyes SpringWorks Therapeutics in potential pharma deal

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-02-12T12:30:32+05:30 | Updated On 12 Feb 2025 12:30 PM IST

Merck in advanced talks to acquire SpringWorks

New York: Merck KGaA, the German healthcare and technology conglomerate, has announced that it is in advanced negotiations to acquire SpringWorks Therapeutics, a commercial-stage biopharmaceutical company.

The statement from Merck confirmed an earlier report by Reuters, indicating that discussions regarding the potential acquisition are ongoing. However, the Darmstadt-based company emphasized that no legally binding agreement has been signed, and there is no certainty that a deal will be materialized.

SpringWorks declined to comment.

If the talks are successful, a deal could be signed in the coming weeks, three sources told Reuters, requesting anonymity as the discussions are confidential. They did not disclose the exact terms being discussed.

SpringWorks' shares closed 34% higher on Monday, giving the company a market value of around $4 billion. The stock initially jumped nearly 49% on the Reuters report, and touched its highest level since April 2022.

Dealmaking in the U.S. healthcare sector is showing signs of picking up, after a slowdown in activity in 2024 as large pharmaceutical companies took a breather to integrate big acquisitions they completed the previous year. Johnson & Johnson last month agreed to buy Intra-Cellular Therapeutics for about $14.6 billion.

Stamford, Connecticut-based SpringWorks, which listed its shares in New York in 2019, is a commercial-stage biotech firm that develops drugs to treat various forms of cancer, including rare tumors and uterine cancer. Its monotherapy drug for the treatment of desmoid tumors, which are dense, soft-tissue tumors, has been approved in the United States. The company is expecting the approval of a product that treats neurofibromatosis type-1, a rare genetic disorder, later in February.

STRATEGIC BET

A transaction for SpringWorks would rank as one of the biggest pharma deals for Merck in recent years and boost its efforts to build out its cancer treatment pipeline.

Merck has suffered high-profile setbacks recently in late-stage drug trials, prompting it to halt development of head and neck cancer drug Xevinapant. A major trial testing multiple sclerosis drug Evobrutinib failed in December 2023.

In its most recent quarterly earnings, Merck reported a 12% rise in adjusted quarterly earnings, helped by temporarily lower spending on drug development and a rebound in demand for its specialty materials.

"Given Merck KGaA’s existing franchise in oncology, which constitutes about 25% of its healthcare sales in 2024, we see the potential acquisition of SpringWorks as likely complementary and giving potential for synergies," analysts at JPMorgan wrote in a note.

"Most importantly, given the projected size of the SpringWorks products, we see the assets potentially more than offsetting the erosion from LOEs (loss of exclusivity) and competition that Merck is facing."

Merck has not shied away from splashy takeovers in the past. In 2015, the company agreed to buy U.S. lab equipment supplier Sigma-Aldrich for $17 billion, its biggest-ever deal. In 2019, Merck acquired U.S. electronics materials manufacturer Versum for 5.8 billion euros ($5.97 billion).

In an interview in January, Merck's CEO said a recovery in sales growth at its major businesses would allow the company to take a cautious approach to buying other companies, which are expensively priced.

merckmerck newsacquisitionspringworks therapeutics

Source : with inputs

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751